Can daily EGFR pills keep early lung cancer from returning after surgery?
NCT ID NCT07837739
First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time
Summary
Researchers are running a registry study to watch how well EGFR tyrosine kinase inhibitor pills work after surgery in people with early-stage, EGFR-mutant non-small cell lung cancer. About 100 adults, ages 18 to 75, join across five centers, and all have tumors with an EGFR alteration and features that raise the risk of recurrence. Treatment follows routine practice rather than random assignment, so each person and their doctor decide whether to use the pills or simply monitor. The study tracks how long participants stay cancer-free, overall survival, quality of life, and side effects, and it collects tumor tissue and blood samples for genetic analysis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EGFR tyrosine kinase inhibitor pills taken after lung cancer surgery, including gefitinib, erlotinib, icotinib, osimertinib, furmonertinib, and almonertinib
- What this could lead to
- If the approach helps, it could sharpen guidance on which early-stage EGFR-mutant lung cancers benefit from pill therapy after surgery and for how long.
- What could go wrong
- This registry observes routine care rather than assigning treatment, so patients who take the drugs may differ from those who do not, which can muddy comparisons. The 100-person sample is small, and follow-up must stretch years before recurrence patterns become clear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with EGFR-mutant, completely resected high-risk stage IA2 to stage IIB NSCLC/lung adenocarcinoma who are treated and followed at participating thoracic oncology centers in Hubei Province, China.
- Ages
-
18 to 75 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-75 years, male or female, with written informed consent. * Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology. * For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component \>2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection). * EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation. * Complete surgical resection with negative margins (R0); lobectomy or sublobar resection may be included according to the protocol. * No previous antitumor treatment, including no neoadjuvant radiotherapy, chemotherapy, targeted therapy, or immunotherapy. * ECOG Performance Status 0-1. * Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L. * Renal function: serum creatinine ≤1.2×ULN. * Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN. * Able and willing to comply with protocol-specified treatment/observation and follow-up. * Adequate tumor tissue available and willingness to provide tissue and blood samples for study analyses. * Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study. Exclusion Criteria: * Contraindication to anesthesia or surgery, or death attributable to the surgical procedure before study enrollment/evaluation. * Any systemic disease incompatible with participation in the clinical study or inability to provide written informed consent. * Pregnancy or breastfeeding. * Known active alcohol or drug abuse or dependence. * Any serious or unstable medical condition or psychiatric disorder that, in the investigator's judgment, would make participation inappropriate. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can blocking TGF-Beta 2 boost immunotherapy in lung cancer?
- New drug CCS1477 tested against tough solid tumors
- Higher-Dose radiation plus immunotherapy tested against advanced lung cancer
- Does a daily pill hold up outside the trial? Real-World lung cancer data put aumolertinib to the test
- Can two targeted drugs keep HER2 lung cancer from coming back?
- Double attack on HER2: two drugs combined against Hard-to-Treat lung cancer